Caplin Steriles Gains US FDA Approval for Generic Foscarnet Sodium Injection in Antiviral Market

Caplin Steriles has secured US FDA ANDA approval for generic foscarnet sodium injection, positioning the Chennai-based sterile injectables manufacturer to compete in a US market segment that recorded approximately $15 million in sales over the last 12 months. For QA directors and regulatory leads at competing US-facing CMOs, the approval signals continued momentum among Indian sterile injectable manufacturers navigating the agency's increasingly rigorous pre-approval inspection cycle.

Foscarnet sodium injection is indicated for the treatment of cytomegalovirus (CMV) retinitis and herpes simplex virus (HSV) infections, primarily in immunocompromised patients. The product sits within a narrow but clinically critical antiviral injectable segment where supply reliability and sterility assurance standards carry significant weight with hospital formulary committees and GPO procurement teams.

The approval adds to a pattern of Indian manufacturers advancing through 21 CFR Part 211-compliant sterile manufacturing frameworks to capture niche injectable opportunities in the US generics market. Foscarnet sodium's relatively contained market size, combined with its complex handling requirements, has historically limited the number of approved generic entrants, making each new ANDA approval consequential for competitive pricing dynamics.

For plant heads overseeing sterile fill-finish operations, the Caplin approval is a reference point on what FDA expects from facilities producing high-pH, nephrotoxic parenteral products under current GMP. Process validation documentation, container-closure integrity testing, and extractables and leachables data for this class of product are areas where inspection readiness directly determines approval timelines.

Caplin Steriles operates dedicated US FDA-inspected sterile manufacturing infrastructure, and this approval extends its injectable portfolio into the antiviral category alongside its existing oncology and critical care lines.

The $15 million annual US sales figure for the reference product establishes the near-term revenue ceiling for generic entrants, though market share distribution will depend on launch timing, contract manufacturing commitments, and the number of additional ANDAs the agency clears for this molecule.

Source: Media4Growth via Indian Pharma Post, 17 May 2026.